Frequently Asked Questions
The market is segmented based on , By Type (Primary Dysmenorrhea, Secondary Dysmenorrhea), Treatment Type (Medication, Therapy, Surgery, Others), Diagnosis (Ultrasound, Laparoscopy, CT scan, magnetic resonance imaging (MRI), Others), Mode of Prescription (Over the Counter, Prescription), Route of Administration (Oral, Parenteral, Implants, Others), End-Users (Hospitals, Specialty Clinics, Homecare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others) – Industry Trends and Forecast to 2030.
.
The Global Menstrual Cramps Treatment Market size was valued at USD 4338.30 USD Million in 2022.
The Global Menstrual Cramps Treatment Market is projected to grow at a CAGR of 8.3% during the forecast period of 2023 to 2030.
The major players operating in the market include Pfizer, GlaxoSmithKline, Novartis, Mylan, Teva Pharmaceutical Industries, Sanofi, AstraZeneca, Johnson & Johnson Private Limited, Merck & Co., F. Hoffmann-La Roche, Baxter, Bayer, Eli Lilly and Company, Sun Pharmaceutical Industries, Aurobindo Pharma, Lupin, Allergan, AbbVie, Abbott, Bausch Health Companies..
The market report covers data from the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E., South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
